telegenisysinc
10+ Views

Telegenisys releases Nursing Home Reference Dataset for VMR 2.0 series

Professionals often struggle with very large medical records specifically related to Nursing Homes because they create a large volume of pages due to the nature of care provided.
The minimum data set for Nursing Home standard of care helps expose relevant information based on the use of the specific requirements of the clients.
Telegenisys announces the release of Nursing Home Reference Dataset 1.1 in VMR 2.0 series for matrix referencing medical records which improves comprehension and speed of these medical record reviews.

Comment
Suggested
Recent
Cards you may also be interested in
What COVID-19 Impacted on Artificial Blood Substitutes Market in Healthcare Industry ?
Impact of COVID-19 on Artificial Blood Substitutes Market in Healthcare Industry COVID-19 pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature and lack of availability of its vaccine. As a result, the greatest medical challenge in the 21st century is yet to be faced by physicians worldwide. Though the emergence of the virus can be traced back to Asia, many European countries along with the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. The COVID-19 has been declared as a pandemic by World Health Organization (WHO) due to its increased spread across the globe. After the declaration of the pandemic, various countries announced the complete lockdown such as India, China, and other Asian countries to decrease its spread. According to the latest situation report by World Health Organization (WHO) stated 175 million cases of the corona have been reported globally and 4 million patients are dead due to the coronavirus. On a slightly positive note, a total of 158 million people have recovered and total of 2 million vaccine doses have been administered as well. The COVID-19 has led to the lockdown all around the world which has impacted the artificial blood substitute market tremendously. Moreover, the coronavirus leads to a drop in oxygen in the body, and artificial blood substitute may be the solution for that as it offers high oxygen-carrying capacity in comparison to the human blood. Although, rising awareness regarding the toxicity and side effects of artificial blood substitutes coupled with the low number of FDA approval for artificial blood substitute products may hamper the growth of the market on a global level. The COVID-19 pandemic has affected the artificial blood substitute market positively on a global level. The persistence of COVID-19 for a longer period has affected the supply and demand chain of human blood and blood component. During the COVID-19 pandemic, manufacturers are expecting a boost in their market as the number of patients needing blood is also increasing with the ongoing diseases and the number of blood donor decreased. Due to this, the demand for artificial blood substitutes has increased which will propel the growth of the global artificial blood substitute market. IMPACT ON SUPPLY AND DEMAND With the ongoing pandemic, the government has put restrictions on the movement of citizens as well as industries, educational institutions, and social organizations. Due to which everything is closed across the country and majorly the blood donation camp are organized by these sectors but with the restriction on movement there is a hold on that. As there is no prior arrangement for blood donation which has worsened the supply of blood as people are not willing to visit blood centres for donation. For instance, · According to the International Society of Blood Transfusion, the survey has shown that blood donations have dropped in 32 countries, and the COVID-19 pandemic has reduced the overall supply of blood. With the limited supply of human blood, the demand for artificial blood substitutes has increased, which will boost the growth of the market even in the future. People suffering from a disease such as a thalassemia, sickle cell anaemia, haemophilia, leukaemia cancer, and other blood-related diseases need regular blood transfusion even during COVID-19 condition which has increased the demand for artificial blood substitute. Even cancer patients, obstetric conditions, victims of accidents need blood products. The supply chain disruption of blood has driven the demand for artificial blood substitutes across the globe. THE INCREASING DEMAND FOR BLOOD TRANSFUSION IS LEADING THE ARTIFICIAL BLOOD SUBSTITUTES MARKET. The demand for artificial blood is increasing for the blood transfusion process as it offers various advantages over human blood. The artificial blood could be stored for a longer period even for 3 years at room temperature whereas the human blood could only be stored for 42 days. Artificial blood also reduces the risk of contamination of other diseases such as hepatitis, AIDS, and others. One of the main factors driving the artificial blood substitute market is its high oxygen-carrying capacity as one of the major crises in COVID-19 patients is the drop in oxygen level, which could be recovered with artificial blood substitutes as it has high oxygen-carrying capacity in comparison to the human blood. The rising incidence of blood-related diseases increases the demand for blood transfusion and the shortage of blood during a pandemic will push the growth of the global artificial blood substitutes market. For instance, · According to Zee Entertainment Enterprises Limited, American Red Cross has seen a 10% rise in demand for red blood cells for hospital trauma centers as compared with the demand in 2019. The rising incidence of blood-related diseases and increase in the need for blood and blood transfusion will boost the market growth in the future. Also, the artificial blood substitute is preferred over the human blood as it is compatible with all blood types and can be given to the patients regardless of their blood type. Moreover, the vaccinated people are not donating blood which has affected the blood supply and will eventually boost the growth of artificial blood. For instance, · According to Cable News Network LP, LLLP, the regulations have been laid down that the vaccinated individual won’t be able to donate for at least 60 days, which could trigger a major shortage in the blood bank. · In May 2021, According to Science Wire, National Blood Transfusion Council (NBTC) has issued an order stating a person cannot donate blood 28 days post-vaccination, and people who received Covaxin have to wait for 56 days and who received Covishield, up to 70 days. The regulations for donating blood post-vaccination will affect the supply chain of blood and will lead to its increased demand and create a great opportunity for artificial blood substitutes. AFTERMATH OF COVID-19 The COVID-19 outbreak has impacted the healthcare system and has led to a decrease in the supply of blood. As coronavirus caused severe acute respiratory syndrome and due to which a lot of people died. The crucial staff members of the hospital also died during the pandemic and along with that, there is a reduction in the number of donations of blood and blood component. Therefore, with decreased blood donation the demand for blood has been increased to support ongoing critical needs and to treat a large number of patients. Hence, the professionals are looking out for options for instance artificial blood substitutes to treat patients on time. The COVID-19 pandemic has majorly affected the healthcare system and blood supply and demand across the globe. For instance, · According to World Health Organisation (WHO), a survey has been conducted in the African region which shows the impact of COVID-19 on blood supply and its demand, according to the data the total number of blood donations has dropped in 32 countries and rise in only 5 countries. Also, the proportion of blood drive has decreased in 21 countries. With the rising incidence of blood-related diseases, the demand for blood will be increased and due to the lack of availability of fresh blood, the need for artificial blood will be increased after the COVID-19 outbreak. The COVID-19 pandemic has led to the reduction of blood and blood-related activities, including demand and supply, and has affected the healthcare system on a major level. CONCLUSION Pandemic has taken a toll on every aspect of life, including the global economy. With the significant downfalls in many sectors, a collaborative effort of government, industry players, and consumers can win the fight against COVID-19. COVID-19 pandemic has affected the artificial blood substitute market positively. The demand for blood has increased immensely especially in the COVID-19 crisis as the number of patients needing blood has increased whereas the number of donors decreased. This factor will boost the growth of the market. During the COVID-19 outbreak, the government has posed a ban on movement due to which the blood donation camps could not be organized, which is the main reason that the supply of human blood has decreased. Although the demand for blood is much higher than the donation, it requires an alternate solution. The rising awareness regarding the advantages of artificial blood over human blood will propel market growth globally. Moreover, the incidence of blood-related diseases and the demand for blood transfusion has increased especially in COVID-19 time. Therefore, the need for artificial blood substitute which can be stored for a longer period and can be given to the patients irrespective of their blood type will drive the market growth even in the future. Therefore, the increasing prevalence of diseases will increase the demand for artificial blood substitutes and the market will grow even after the COVID-19 is over.
Research Antibodies and Reagents Market worth $14.1 Billion by 2025 - Exclusive Report by MarketsandMarkets™
According to the new market research report "Research Antibodies and Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blotting, Flow Cytometry), Application (Proteomics, Drug Development), End User - COVID-19 Impact - Global Forecast to 2025", published by MarketsandMarkets™, the global market size is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period. The growth is due to evolution of market owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research reproducibility, and increasing R&D activity and expenditure in the life sciences industry. Fueled by the growing demand for personalized medicine and structure-based drug design, the global market is expected to witness significant growth in the coming years. Browse in-depth TOC on "Research Antibodies and Reagents Market" 220 – Tables 45 – Figures 278 – Pages Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793 The COVID-19 outbreak has boosted research activity due to efforts to understand the dynamics of the infection. We estimate that the major share of research antibody and reagent manufacturing, along with personalized medicine, will grow at a stable pace in the next five years. Due to the increase in research activity, both the availability of funding for research and the demand & manufacturing of reagents and antibodies are expected to grow. As companies after pandemic have scaled up their operations for testing and tracking the infection of COVID-19. This has given a chance for growth in profits for companies operating in the NGS and PCR markets. The growth in revenue is 5–7%, as COVID-19 testing has increased with the use of the latest technology of genetic and molecular testing. The shift in demand for research for COVID-19, neurobiology, and oncology has created a huge scope for testing solutions, such as western blotting, flow cytometry, ELISA, and drugs for researchers and laboratories. The antibodies segment is expected to grow at the highest CAGR during the forecast period Based on product, the research antibodies market is segmented into reagents and antibodies. The antibodies segment is expected to grow at highest CAGR in forecast period. This is due to the research-use antibodies offer high specificity and selectivity and are used ubiquitously in biochemical and medical research for protein-target identification, regulatory characterization, and discovery. The primary antibodies segment is accounts for the largest share of the research reagents market Based type, the research reagents market is segmented into primary antibodies and secondary antibodies. The primary antibodies segment held the largest share of the global research antibodies market in 2019. This segment is witnessing a strong growth due to the use of these antibodies in numerous types of assay formats. Their accuracy in biomarker detection and their high specificity and sensitivity are also driving their adoption The media & sera reagent is expected to account for the largest share of the market, by type, in 2019 Based type, the research antibodies and reagents market is segmented into media &sera, stains & dyes, fixatives, buffers, solvents, enzymes, probes and other reagents. The media & sera reagent segment held the largest share of the global research antibodies market in 2019. The large share of this segment is primarily attributed to the use of these components in all types of assays, cell cultures, and techniques. The western blotting segment is expected to account for the largest share of the market, by technology, in 2019 Based on technology, the research antibodies market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. Western blotting segment is expected to grow at highest CAGR in forecast periods (2020-2025). This is due to the high adoption of this technique in proteomic and genomic research. The results achieved are easy to interpret, unique, and unambiguous, making it suited for evaluating levels of protein expression in cells, monitoring fractions during protein purification, and comparing the expression of a target protein from various tissues. The pharmaceutical & biotechnology segment is expected to grow at the highest CAGR during the forecast period Based on end user, the research reagents market is segmented into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations. The growth of this segment is due to antibodies provide a gold standard for the detection of a biomolecule or a pathway and are even capable of detecting specific changes in potential drug targets. Additionally, highly specific reagents are used to measure pharmacokinetic parameters in the preclinical and clinical development of biological drugs. The increasing demand for personalized medicine and government initiatives in this sector are the key market drivers for this segment. Get 10% Customization on this Research Report:-https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=94212793 The APAC market is expected to grow at the highest CAGR during the forecast period The Asia Pacific research reagents market is expected to grow at the highest CAGR from 2020 to 2025.The growth of this market is primarily due to growing proteomics and genomics research and increasing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics in the region. Also, high-growth countries, such as China, India, Japan, South Korea, Taiwan, Australia, and Singapore are the major contributors to the Asia Pacific research antibodies and reagents market. This region is expected to grow at the highest pace during the forecast period primarily due to growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics. The prominent market players are Thermo Fisher Scientific (US), Merck Group (Germany), Abcam plc (UK), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US). Browse Related Reports: Flow Cytometry Market by Technology (Cell-based, Bead-based), Product (Analyzer, Sorter, Reagents, Consumables, Software), End user (Academia, Research Labs, Hospitals, Clinical Laboratories, Pharma-Biotech Cos), Application - Global Forecasts to 2025 https://www.marketsandmarkets.com/Market-Reports/flow-cytometry-market-65374584.html
Order xanax online in usa at overnight delivery
What is Xanax's new guide 2021? Xanax is a medicine mainly used in anxiety and panic attacks. Also, if any disease symptoms, you see and feel it. Then your doctor properly guides you. You can buy Xanax medicine online. Xanax new guide information available for the best consumption of this medicine. You can order Xanax medicine online. visit here: https://onlinehealths.com/product-category/buy-xanax-online/ call us: +1(707) 510-0015 When to take Xanax As in, you know that without reason, you should not consume any medicine. But if you suffer from this anxiety and panic disorder feels. Then in those circumstances, you can take Xanax medicine. Thus, if you do not need to, avoid it. But Xanax medicine is specially made to reduce your anxiety and panic attacks. What is Alprazolam used for? Xanax medicine is used to control your anxiety and panic attacks. That's why it is using more in this bearing time. Xanax's medicine generic name is Alprazolam. But I will remind you. By which you can stay safe from the adverse effects. Then, first of all, you should take consultancy from your doctor for the proper consumption of this medicine. What online doctor can prescribe Xanax? Also, If you seem like you have to suffer from any anxiety-related problems and any panic attacks you are facing, so, in those circumstances, you will have to take Xanax medicine. Therefore, if you want to take this medicine, you can take it from online trustworthy USA's websites. At these websites there is no risk of duplicate and fake medicine. Thus, you can easily buy from there. Can I purchase Xanax online in the USA? Suppose you need to take Xanax medicine. Due to bear anxiety and panic attacks. Then consumption of this medicine is suitable to treat your problem. Also, you can order Xanax online medicine from USA's trustworthy websites. Also, from where you can get some discounts and products originality. xanax(Alprazolam) side effects As you know that all medicines are different for also, using different salts. FDA approved for the effects of overdose consumption. So, if you take this medicine with another medicine and you also consume it in an overdose. Then in this atmosphere, after consuming this medicine, you will see some side effects in your body. Thus, I will share with you some adverse effects of medicine consumption. Dizziness and Drowsiness Sex ability may occur Hallucinations Lightheadedness Precautions: Even if you want to take Xanax medicine, then, first of all, you will have to take some precautions while you are using this medicine specially. Because if you do not take care of the precautions, then you can put yourself in trouble. Also, overdose consumption can increase your problem. During consumption, you should not take any harmful food and alcohol, or any medicine. That'sThat's why it can increase your problem. What should you avoid while taking Alprazolam? During the consumption of Xanax, you have to know about something. Also, you should avoid harmful things like alcohol, caffeine, and any other medicine. How often can I take Xanax 0 .25 mg? Xanax 0.25 mg medicine you can take three times a day. Conclusion Thus, you know that without reason, you should not consume any medicine. But if you suffer from this anxiety and panic disorder feels. Then in those circumstances, you can take Xanax medicine. Also, you can buy and order Xanax medicine online.
What COVID-19 Impacted on Prenatal Testing & Newborn Screening in Healthcare Industry ?
Impact of COVID-19 on Prenatal Testing and Newborn Screening in Healthcare Industry OVERVIEW AFTERMATH OF COVID-19 AND GOVERNMENT ROLE A recent SARS-CoV-2, virus has caused a general pandemic of respiratory disease, called COVID-19. The infection initially showed up in Wuhan, a city in China, in December 2019. The patients experiencing COVID-19 are cautiously dealt with all the safety measures since this sickness spreads quicker through actual contact. There are now numerous vaccines in use. The first mass vaccination program commenced in early December 2020 and as of 15 February 2021, 175.3 million vaccine doses have been administered. World Health Organization (WHO) issued an Emergency Use Listing (EULs) for the Pfizer COVID-19 vaccine (BNT162b2) on 31 December 2020, issued another two EULs for two versions of the AstraZeneca/Oxford COVID-19 vaccine, manufactured by the Serum Institute of India and SKBio on 15 February 2021. On 12 March 2021, WHO issued a EUL for the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson) As per the WHO report, globally, as of 2 June 2021, there have been 170,812,850 confirmed cases of COVID-19, including 3,557,586 deaths, reported to WHO. As of 2 June 2021, a total of 1,581,509,628 vaccine doses have been administered. As per the WHO report, in the United States of America, from 3 January 2020 to 4:26pm CEST, 2 June 2021, there have been 32,942,677 confirmed cases of COVID-19 with 588,866 deaths, reported to WHO. As of 27 May 2021, a total of 294,270,594 vaccine doses have been administered. Even though immunization is found for COVID-19, safeguards incorporate incessant hand-wash, wearing a face veil, and keeping up social separating. The goal of new born screening is the pre-symptomatic detection of infants with congenital conditions so that treatment may be commenced at the earliest to prevent, or improve, the long-term In light of the fiery impacts of the infection, there are hypothetical dangers that the viral contamination could delay the prenatal testing and newborn screening as there have been limited visits to the hospitals and testing centers due to the lockdown imposed by the government in different countries. Newborn screening is a public health service done in every U.S. state. A cluster of health disorders that remains inconspicuous at birth is tested for every newborn. Every newborn is tested for a group of health disorders that aren't otherwise found at birth. With a simple blood test, doctors can check for rare genetic, hormone-related, and metabolic conditions that can cause serious health problems. Newborn screening lets doctors diagnose babies rapidly and commence treatment as soon as possible. STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS The key players engaged in global wound healing manufacturing are making improvements to keep the speed during COVID-19. They are taking every single choice cautiously to expand on a consistent schedule for the market. The manufacturers are likewise giving a great deal of consideration in improving inventive items that can be utilized for the attractive impacts. Organizations working in the minimally invasive gastrointestinal surgical systems market embrace a few systems, including joint effort, arrangements, association, and market development, to improve their business. These essential choices by the organizations must give huge occasions to the market players working in the minimally invasive gastrointestinal surgical systems market. For instance, · December 2017, Eone-Diagnomics Genome Center (EDGC), a Korean genetic analysis company, announced its decision to apply machine learning-based artificial intelligence (AI) technology to its non-invasive prenatal test (NIPT) NICE 0. In 2019, AI specialist FDNA and PerkinElmer Genomics partnered to launch Face2Gene Labs for newborn testing. This decision enabled the company to flourish further in the market and helps in revenue generation IMPACT ON DEMAND Since the pandemic, due to the lockdown situation, the economic growth of a country is declining day by day. And the manufacturing units for various items shut down due to the non-availability of manpower. There will be opportunities in the coming time for manufacturers of digital health technologies to position themselves for the COVID-19 recovery. When COVID-19 responses ease, there will be an excess of elective surgeries procedures in emergency clinics. The pre-appointment programs can help smooth out the planning, arrangement, and conveyance of the medical professionals and the doctors. For instance, · CVS is a type of diagnostic test performed between 10.5 to 13.5 weeks of pregnancy. The procedure involves obtaining a small tissue sample from the placenta by inserting a thin needle through the woman’s abdomen or using a small catheter inserted through the cervix by a doctor. The method used depends on the location of the baby and the placenta. · Another diagnostic test called amniocentesis is performed from 15 weeks of pregnancy onward. A thin needle is inserted through the woman’s abdomen into the amniotic sac to withdraw a small sample of fluid from around the developing baby in amniocentesis. Cloud-based stages have an extraordinary preferred position in permitting the clinician and their representatives to design cases distantly while travel and medical clinic access limitations are set up. With the careful plans and embeds chose early, embed providers and emergency clinics have the chance to enhance their stock and creation (on account of patient-explicit custom parts) to address the accumulation of cases once the circumstance permits effectively. IMPACT ON SUPPLY Because of the pertinacious COVID-19 lockdown, sanctions have been forced by administrations of different nations. These limitations and boundaries across the nation’s borders prompted a diminishing stockpile because of restricted materials and labor force, and the halting of assembly line. The supply chain units are taking stringent measures and risk mitigation protocols to provide the devices to the manufacturers to the customer. The presence of key market players for the development and launch of the prenatal testing and new born screening systems will increase the net sales and show a surplus growth in the market. Additionally, the manufacturers are also taking crucial steps to ensure the availability of raw materials by and also they have to look into the quality of products. But since the demand is increasing day by day, to meet the demand, the major manufacturers and suppliers collaborate to ensure the supply of raw materials. IMPACT ON PRICE Because of COVID-19, the market is upset to a major level. The few foundations need to stay shut while others to downsize the activities or put on pause extension plans as they attempted to endure the uncommon emergency. Now, as the demand for telehealth innovation is turning out to be very demanding by human being, and this will make the market more competitive due to new and more innovative equipment that will be launched by the makers, by decreasing the overall cost of the new and innovative prenatal testing & newborn screening systems and solutions. The current COVID-19 episode has influenced every industry on earth, and prenatal testing & newborn screening market is no exemption. There has been a tremendous and sudden lessening in the volume of elective joint substitutions worldwide as wellbeing situation legitimately organize their COVID-19 reaction. States must develop and implement policies that allow for interstate licensure and practice of medicine (entailing the use of telemedicine) to enable consultation and communication to remote areas and ensure the swift flow of information across state lines. CONCLUSION All three components (blood spot screening, hearing, and CCHD screening) of newborn screening are requisite for babies and should still occur during the COVID-19 pandemic. Babies with newborn screening conditions still need to undergo monitoring and treatment promptly for newborn screening conditions during the COVID-19 pandemic. State and territory newborn screening programs are still conducting the newborn screening. Babies should still receive newborn screening during the COVID-19 pandemic. Local manufacturers are now adapting new and better characteristics to create enormous supply measures to address the issue in coming fates and also the government is also helping to defeat all the difficulties faced in these unprecedented times. It is estimated that the COVID-19 pandemic outbreak has a negative impact on the growth of the global minimally invasive gastrointestinal surgical systems market. The growing prevalence of genetic diseases has necessitated a stable healthcare network and adequate emergency medical services (EMS). However, certain challenges in Research and Development and the loss of patent of the devices may hamper the market growth. The sales of prenatal testing and newborn screening tests services and related goods by entities (organizations, sole traders and partnerships) that offers prenatal testing and newborn screening tests, which aids in determining various genetic and chromosomal diseases, to furnish timely medical or surgical treatment of a condition before or after birth. Moreover, the wider adoption of these systems is expected to increase to meet the rising demand for prenatal testing and newborn screening across the globe and overcome the shortage of healthcare professionals to perform such testing and screening. In the wake of the pandemic, current industry players with a substantial market share that consumed cash-rich and good management teams would prosper. Making the correct actions would enable businesses to demonstrate preparation and offer end-users reliability
How COVID-19 Impacted on Electromyography Devices ?
Impact of COVID-19 on Electromyography Devices in Healthcare Industry OVERVIEW AFTERMATH OF COVID-19 AND GOVERNMENT ROLE A recent SARS-CoV-2 virus has caused a general pandemic of respiratory disease, called COVID-19. The infection initially showed up in Wuhan, a city in China, in December 2019. The patients experiencing COVID-19 were dealt with cautiously with all the safety measures since this disease spreads aggressively through actual contact. There are now numerous vaccines in use. The first mass vaccination program commenced in early December 2020, and as of 15th February 2021, 175.3 million vaccine doses have been administered. World Health Organization (WHO) issued an Emergency Use Listing (EULs) for the Pfizer COVID-19 vaccine (BNT162b2) on 31st December 2020, issued another two EULs for two versions of the AstraZeneca/Oxford COVID-19 vaccine, manufactured by the Serum Institute of India and SKBio on 15th February 2021. On 12th March 2021, WHO issued a EUL for the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson). As per the WHO report, globally, as of 5th June 2021, there have been 179,513,309 confirmed cases of COVID-19, including 3,895,661 deaths, reported to WHO. As of 23rd June 2021, a total of 2,624,733,776 vaccine doses have been administered. In India, from 3rd January 2020 to 10:21 am CEST, 25th June 2021, there have been 33,257,768 confirmed cases of COVID-19 with 597,727 deaths, as reported to WHO. As of 17th June 2021, a total of 317,983,185 vaccine doses have been administered. Even though immunization is found for COVID-19, safeguards incorporate incessant hand-wash, wearing a face mask, and keeping up social separating. NCS and EMG findings indicate a direct action of COVID-19 on nerves and muscles. SARS−COV-2 demyelinating polyneuropathy and elements of myopathy could be new pathological entities to be considered in the COVID-19 management. More studies would be required to confirm these electrophysiological findings. In light of the fiery impacts of the infection, there are hypothetical dangers that the viral contamination could delay the early testing and detection through electromyography as there have been limited visits to the hospitals and testing centers due to the lockdown imposed by the government in different countries. The goal of electromyography is the pre-symptomatic detection of the aberrant electrical activity of the skeletal muscles so that treatment may be commenced at the earliest to prevent, or improve, the long-term consequences of neuromuscular diseases. IMPACT ON DEMAND Since the pandemic, due to the lockdown situation, the economic growth of a country is declining day by day. And the manufacturing units for various items shut down due to the non-availability of manpower. Coronavirus disease (COVID-19) causes acute respiratory illness ranges from mild to severe pneumonia with respiratory failure. Moreover, neurological involvement is more common in severely affected patients with COVID-19 than in those with less severe illness. Electromyography devices are required to treat severe coronavirus disease (COVID-19) patients, Moreover, the growing number of COVID-19 patient pools in developed, as well as developing countries illustrates the huge future demand for electromyography devices across the globe. For instance, · According to the World Health Organization (WHO), till 25th February 2021, there have been 112,209,815 confirmed cases of COVID-19, including 2,490,776 deaths Thus, the growing cases of coronavirus disease (COVID-19) indicate a huge demand for electromyography devices across the globe. Henceforth, it is estimated that the global electromyography devices market is anticipated to boom up in the forecasted period. IMPACT ON SUPPLY Because of the pertinacious COVID-19 lockdown, sanctions have been forced by administrations of different nations. These limitations and boundaries across the nation’s borders prompted a diminishing stockpile because of restricted materials and labour force and the halting of the assembly line. The COVID-19 pandemic has transformed many organizations’ business environments. Supply availability has been hampered by a number of issues, including export and travel restrictions by some producing countries, and the lockdown has forced suppliers to (temporarily) shut down. To minimize supply chain crises, healthcare organizations have been firmly monitoring the supply chain with the assumption that the COVID-19 outbreak may adversely impact the supply chain of electromyography devices, including shortages of electromyography devices or potential disruptions in its supply chains. The supply chain units are taking stringent measures and risk mitigation protocols to provide the devices to the manufacturers to the customer. The presence of key market players for the development and launch of the electromyography devices will increase the net sales and may show a surplus growth in the market. Additionally, the manufacturers are also taking crucial steps to ensure the availability of raw materials by and also they have to look into the quality of products. But since the demand is increasing day by day, so as to meet the demand, the major manufacturers and suppliers are collaborating with each other’s to ensure the supply of raw materials. To manage such critical situations, many organizations are looking forward to improving and diversifying the supply chain model in all aspects. A diversified supply chain model is anticipated to enhance the availability of electromyography devices in the market as well as increase end-to-end visibility. The resulting COVID-19 pandemic has shown the various ways for supply chain management, which may be effective within a remote working environment. IMPACT ON PRICE Because of COVID-19, the market is upset to a major level. The few foundations have been stay shut while others had downsized the activities or put a pause to the extension plans as they attempted to endure the uncommon emergency. States must develop and implement policies that allow for interstate licensure and practice of medicine (entailing the use of telemedicine) to enable consultation and communication to remote areas and ensure the swift flow of information across state lines. Now, as the demand for telehealth innovation is turning out to be very demanding by human beings, this will make the market more competitive due to new and more innovative equipment that will be launched by the makers, by decreasing the overall cost of the new and innovative new product launches. The current COVID-19 episode has influenced essentially every industry on earth, and the electromyography devices market is no exemption. There has been a tremendous and sudden lessening in the volume of elective joint substitutions worldwide as wellbeing situation legitimately organize their COVID-19 reaction. STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS The key players engaged in global wound healing manufacturing are making improvements to keep the speed during COVID-19. They are taking every single choice cautiously so the development can be expanded on a consistent schedule for the market. The manufacturers are likewise giving a great deal of consideration in the improvement of inventive items that can be utilized for the attractive impacts. Organizations working in the electromyography devices market are embracing a few systems, including joint effort, arrangements, association, and market development to improve their business. These essential choices by the organizations are required to give huge occasions to the market players working in the electromyography devices market. A large pool of the population is affected by the COVID-19 virus, and its spread is expanding across the world in the last few months. To deal with the COVID-19 outbreak challenges, many electromyography devices market players are creating new strategies. To tackle the pandemic situation and to increase the company revenue and growth, companies are now opting for digital media such as telecommunication, mobile applications, webinars, and other digital media to support patient requirements. Moreover, to accomplish the market demand, small as well as major market players utilizing the strategy such as partnerships, agreements, and organizing conferences. It is predicted that these strategies are anticipated to escalate up the company revenue and its growth in the forecasted period. For instance, · In April 2020, Neurosoft S.A. organized NYC Neuromodulation 2020 Conference. This conference has anticipated enhancing the company’s presence in the global market. Furthermore, for the economic recovery after the pandemic of COVID-19, the manufacturers of electromyography devices have to adopt several types of strategic initiatives in terms of increasing R and D activities, conduct numerous types of market surveys to know the current situation and mind-set of consumers towards their need. The increasing R and D activities will help the manufacturers to launch the advanced devices by knowing the advanced technology or need of the end-user. For instance, · In August 2020, NIHON KOHDEN CORPORATION launched Version 12 of the Polysmith software used in Polysomnography Devices. This new version of software launched by the company includes more than 40 market-driven features, which aids in good analysis and outcomes. Thus, this product launch by the company leading to enhance the sales growth of the company. CONCLUSION It is estimated that the COVID 19 pandemic outbreak is having a positive impact on the growth of the global electromyography devices market owing to the elevation in demand for electromyography devices. Moreover, many governments and organizations are exclusively focusing on the rapid recovery of COVID-19 patients, and this priority, as well as the essential requirement, is illustrating the further growth of the electromyography devices market. Many government bodies and major electromyography devices market players are closely associated with patients as well as healthcare professionals for better patient health as well as experience. It can be concluded that the COVID 19 pandemic situation has a significant impact on the global electromyography devices market, including the price and demand of electromyography devices. For instance, · December 2017, Eone-Diagnomics Genome Center (EDGC), a Korean genetic analysis company, announced its decision to apply machine learning-based artificial intelligence (AI) technology to its non-invasive prenatal test (NIPT) NICE0. In 2019, AI specialist FDNA and PerkinElmer Genomics partnered to launch Face2Gene Labs for newborn testing. This decision enabled the company to flourish further in the market and helps in revenue generation.
How Impacted COVID-19 on Minimally Invasive Gastrointestinal Surgical Systems in Healthcare Industry ?
Impact of COVID-19 on Minimally Invasive Gastrointestinal Surgical Systems in Healthcare Industry OVERVIEW A recent SARS-CoV-2, virus has caused a general pandemic of respiratory disease, called COVID-19. The infection initially showed up in Wuhan, a city in China in December 2019. The patients experiencing COVID-19 are dealt with cautiously with all the safety measures since this sickness spreads quicker through actual contact. There are now numerous vaccines in use. The first mass vaccination program commenced in early December 2020 and as of 15 February 2021, 175.3 million vaccine doses have been administered. World Health Organization (WHO) issued an Emergency Use Listing (EULs) for the Pfizer COVID-19 vaccine (BNT162b2) on 31 December 2020, issued another two EULs for two versions of the AstraZeneca/Oxford COVID-19 vaccine, manufactured by the Serum Institute of India and SKBio on 15 February 2021. On 12 March 2021, WHO issued a EUL for the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson). · As per the WHO report, globally, as of 16 May 2021, there have been 162,177,376 confirmed cases of COVID-19, including 3,364,178 deaths, reported to WHO. As of 11 May 2021, a total of 1,264,164,553 vaccine doses have been administered. · As per the WHO report, In the United States of America, from 3 January 2020 to 16 May 2021, there have been 32,574,504 confirmed cases of COVID-19 with 579,664 deaths, reported to WHO. As of 6 May 2021, a total of 256,126,513 vaccine doses have been administered. · As per the European Centre for Disease Prevention and Control as of week 2021-13, 27 513 674 COVID-19 active cases and, 627 242 deaths have been reported in the EU/EEA. Even though immunization is found for COVID-19, safeguards incorporate incessant hand-wash, wearing a face veil, and keeping up social separating. IMPACT ON DEMAND Since the pandemic, due to the lockdown situation, the economic growth of a country is declining day by day. And the manufacturing units for various items shut down due to the non-availability of manpower. There will be opportunities in the coming time for manufacturers of digital health technologies to position themselves for the COVID-19 recovery. When COVID-19 responses ease, there will be an excess of elective surgery procedures in emergency clinics. The pre-appointment programs can help smooth out the planning, arrangement, and conveyance of the surgeons and the doctors. Cloud-based stages have an extraordinary preferred position in permitting the clinician and their representatives to design cases distantly while travel and medical clinic access limitations are set up. With the careful plans and embeds chose early, embed providers and emergency clinics have the chance to enhance their stock and creation (on account of patient-explicit custom parts) to effectively address the accumulation of cases once the circumstance permits. IMPACT ON SUPPLY Because of the pertinacious COVID-19 lockdown, sanctions have been forced by administrations of different nations. These limitations and boundaries across the nation’s borders prompted a diminishing stockpile because of restricted materials and labor force and the halting of the assembly line. Additionally, the manufacturers are also taking crucial steps to ensure the availability of raw materials by and also they have to look into the quality of products. But since the demand is increasing day by day, so as to meet the demand the major manufacturing and suppliers are collaborating with each other’s to ensure the supply of raw materials. AFTERMATH OF COVID-19 AND GOVERNMENT ROLE Minimally invasive techniques have revolutionized operative surgery. Computer-aided surgery and robotic surgical systems aim to ameliorate further on currently accessible minimally invasive surgery and open new horizons. In gastrointestinal surgery, robotic surgery is applied to a wide range of procedures but is still in its infancy. Most studies reported that robotic gastrointestinal surgery is workable and safe, provides improved dexterity, better visualization, reduced fatigue, and high levels of precision when compared to conventional laparoscopic surgery. In light of the fiery impacts of the infection, there are hypothetical dangers that the viral contamination could delay the wound healing of the patients as there have been limited visits to the hospitals due to the lockdown imposed by the government in different countries. STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS The key players engaged in global wound healing manufacturing are making improvements to keep the speed during COVID-19. They are taking every single choice cautiously so the development can be expanded on a consistent schedule for the market. The manufacturers are likewise giving a great deal of consideration in the improvement of inventive items that can be utilized for the attractive impacts. Organizations working in the minimally invasive gastrointestinal surgical systems market are embracing a few systems, including joint effort, arrangements, association, and market development to improve their business. These essential choices by the organizations are required to give huge occasions to the market players working in the minimally invasive gastrointestinal surgical systems market. For instance, · In December 2020, Johnson & Johnson Services Inc, participated in the 39th annual J.P. Morgan Healthcare Conference. This helped the company to give the correct knowledge about their product and would help the company to further grow in the coming years. IMPACT ON PRICE Because of COVID-19, the market is upset to a major level, the few foundations need to stay shut while others downsize the activities or put on pause extension plans as they attempted to endure the uncommon emergency. The current COVID-19 episode has influenced essentially every industry on earth, and the minimally invasive gastrointestinal surgical systems market is no exemption. There has been a tremendous and sudden lessening in the volume of elective joint substitutions worldwide as wellbeing situation legitimately organize their COVID-19 reaction. Now, as the demand for telehealth innovation is turning out to be very demanding by a human being, and this will make the market more competitive due to new and more innovative equipment that will be launched by the makers, by decreasing the overall cost of the new and innovative minimally invasive gastrointestinal surgical systems and solutions. CONCLUSION There are no data on the safety, immunogenicity, or effectiveness regarding the treatment of inpatients with wound infections along with mild COVID-19 symptoms. The supply chain units are taking stringent measures and risk mitigation protocols to provide the devices to the manufacturers to the customer. The presence of key market players for the development and launch of the MIS gastrointestinal systems will increase the net sales and may show a surplus growth in the market. Local manufactures are now adopting new and better characteristics to create an enormous measure of muscular embeds to address the issue in coming fates and also the government is helping to defeat all the difficulties that are been faced in the creation of implants. It is estimated that the COVID-19 pandemic outbreak having a negative impact on the growth of the global minimally invasive gastrointestinal surgical systems market. The growing prevalence of chronic diseases has necessitated the need for a stable healthcare network and adequate emergency medical services (EMS). However certain challenges in Research and Development, loss of patent of the devices may hamper the market growth. In fact, a 60–80% decline in elective procedures in the second quarter of 2020 for Europe and the United States, with an additional 40–50 percent decline in the third quarter is estimated. However, post-pandemic the demand for the minimally invasive gastrointestinal systems will surge exponentially as a result of increased demand for contactless procedure facilities. Moreover, the wider adoption of these systems is expected to increase in order to meet the rising demand for surgical procedures across the globe along with overcoming the shortage of healthcare professionals to perform such surgeries. In the wake of the pandemic, current industry players with a substantial market share which consumed cash-rich and have good management teams would prosper. Making the correct actions would enable businesses to demonstrate preparation and offer end-users reliability.
Resuscitation Devices Market Worth $8.7 Billion by 2025 - Exclusive Report by MarketsandMarkets™
According to the new market research report "Resuscitation Devices Market by Product (Defibrillator, Endotracheal & Tracheostomy Tube, Masks, Airways, Laryngoscopes, Resuscitators, Ventilators), Patient Type (Neonatal, Adult), End User (Hospital, Ambulance, ICU), Volume - Global Forecast to 2025", published by MarketsandMarkets™, the Resuscitation Devices Market is projected to reach USD 8.7 billion by 2025 from USD 6.9 billion in 2020, at a CAGR of 4.7% during the forecast period. Browse in-depth TOC on "Resuscitation Devices Market 145 – Tables 36 – Figures   187 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36161641 The growth in the global Resuscitation Devices Market is driven by the rising prevalence of target diseases, increasing demand for emergency care, growing focus on providing public-access defibrillators, high incidence of preterm births, and training & awareness programs on defibrillators. Also, emerging markets and the development of wearable defibrillators are expected to offer growth opportunities for players operating in this market. Airway management devices segment accounted for the largest share of the market in 2019 On the basis of product, the market is segmented into external defibrillators, airway management devices, convective warming blankets, and other resuscitation devices. The airway management devices segment accounted for the largest share of this market in 2019, majorly due to the high prevalence of chronic respiratory diseases, increasing demand for emergency care, and the high incidence of preterm births. Hospitals, ASCs, and cardiac centers segment accounted for the largest share of the market, by end user, in 2019 Based on end user, the market is segmented into hospitals, ambulatory surgical centers (ASCs), and cardiac centers; pre-hospital care centers; and other end users. Hospitals, ASCs, and cardiac centers were the largest end users of resuscitation devices in 2019. The launch of training programs to efficiently undertake and operate lifesaving defibrillation procedures, increasing number of donations with regard to the purchase/implementation of defibrillators, and growing number of trauma cases and road accidents across the globe are few of the major factors driving the growth of this end-user segment. Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=36161641 North America accounted for the largest share of the Resuscitation Devices Market in 2019 In 2019, North America accounted for the largest share of the market. The rising geriatric population, increasing incidence of cardiac and respiratory diseases, and continuous technological advancements and product innovations are the major factors driving the growth of the resuscitation devices market in North America. Also, increasing efforts by governments to provide the necessary care to cardiac arrest victims at public places through public-access defibrillation programs have increased the demand for emergency care in the region. Prominent players in the Resuscitation Devices Market include Koninklijke Philips N.V. (Netherlands), Medtronic plc (Ireland), ZOLL Medical Corporation (US), ResMed, Inc. (US), Physio-Control (acquired by Stryker Corporation, US), Drägerwerk AG & CO. KGaA (Germany), Smiths Medical (US), Ambu (Denmark), Cardinal Health (US), Mindray Medical (China), Nihon Kohden (Japan), Teleflex (US), Salter Labs (US), GE Healthcare (US), Roper Technologies (US), Vyaire Medical (US), Intersurgical (UK), 3M (US), Flexicare (UK), and KARL STORZ (Germany). Browse Related Reports: Airway Management Devices Market by Type (Supraglottic Device (LMAs, OPAs, NPAs), Infraglottic Device (Endotracheal Tubes, Tracheostomy Tubes), Resuscitators, Laryngoscopes), End User (OR, ICU), Patient Age (Adult and Pediatric) - Global Forecast to 2024 Respiratory Care Devices Market by Product (Therapeutic (Ventilator, Mask, PAP Device, Inhaler, Nebulizer), Monitoring (Pulse Oximeter, Capnograph), Diagnostic, Consumables), End User (Hospital, Home Care), Indication - Global Forecast to 2024
How COVID-19 Impacted on Molecular Diagnostics ?
Impact of COVID-19 on Molecular Diagnostics in Healthcare Industry The COVID-19 pandemic has affected the molecular diagnostics market positively on a global level. The persistence of COVID-19 for a longer period has increased the need for molecular diagnostic tools and instruments to diagnose certain diseases, especially the COVID-19 virus. During the COVID-19 pandemic, manufacturers expect a boost in their market as demand for instruments such as PCR or real-time PCR or COVID-19 test kits has increased with the spread of coronavirus. The increasing demand for molecular diagnostics instruments, tools, kits, software, and services will propel the growth of the global molecular diagnostics market. The COVID-19 has led to the lockdown worldwide, which has tremendously impacted the molecular diagnostics market. Moreover, the coronavirus is life-threatening, and proper diagnosis on time has become important and molecular diagnostics are the solution for that. COVID-19 is a contagious disease and can be spread easily via droplet particles. The necessity for the diagnosis of positive cases has increased to ensure prompt care of the affected individual and to curb the further spread of coronavirus in the population. RT-PCR is an important molecular diagnostic instrument that is used to detect SARS-CoV-2. Hence, with the ongoing COVID-19 pandemic, the demand for molecular diagnostics has increased tremendously and will boost the growth of the market. STRATEGIC INITIATIVES BY MANUFACTURERS The rising demand for molecular diagnostics tools, services, instruments and others has led the manufacturers to launch new products in the market for different diseases even during COVID-19 time. Additionally, manufacturers partner with other companies to launch new technology or products or acquire them or merge with them. All these strategies opted by manufacturers is to gain more market share in the market. · In March 2021, Hologic, Inc. acquired diagenode, a molecular diagnostic assay and epigenetics product manufacturer for USD 159 million. · In April 2021, QIAGEN partnered with DiaSorin to launch LIAISON LymeDetect Assay for early diagnosis of Lyme Borreliois. It is based on QantiFERON technology. · In June 2020, Myriad Genetics, Inc. launched AMPLIFY Technology to increase the performance of Prequel NIPS Kit, which is used in prenatal screening. · In March 2021, F. Hoffmann-La Roche Ltd signed a merger agreement with GenMark Diagnostics, Inc. To access their novel technology to test for a broad range of pathogen from single patient sample. · In October 2020, Meridian Bioscience launched a complete solution to support liquid biopsy cancer diagnostics, as it allows direct RNA and DNA detection from liquid biopsy samples such as whole blood. The increasing number of launches, mergers, acquisitions, and partnerships by manufacturers to develop new molecular diagnostics products, services, or technologies to fulfill the rising demand for molecular diagnostics will boost the market's growth. AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVES FOR GROWTH OF THE MARKET The COVID-19 outbreak has become a global public health emergency, and it has increased the need for accurate and rapid molecular diagnostic technology for screening, treatment, isolation, prevention, and control of COVID-19. The demand for primary diagnostic tools that detect antigens or antibodies specific to SARS-CoV-2 infection via nucleic acid detection technique or rapid diagnostic tests has increased. Moreover, the cases for COVID-19 are increasing tremendously, increasing the demand for molecular diagnostics tools, services, and instruments to provide proper diagnosis and treatment to control the spread of COVID-19. Hence, the professionals are also looking out for the technologies, tools, and kits to detect the diseases and treat patients on time. Even after the COVID-19, the molecular diagnostics market will propel globally to treat and diagnose different diseases like cancers efficiently and on time. With the COVID-19 pandemic, the government also gets little concerned about introducing molecular diagnostics tools in the market. For instance, · In August 2020, According to Spandidos Publications, China National Medical Products Administration opened a special channel to approve new pharmaceuticals for urgent clinical needs and 18 nucleic acid detection kits, one sequencing-related equipment, 11 protein detection kits, and software have been approved until April 23, 2020. · In March 2020, Cepheid received Emergency Use Authorization (EUA) from the U.S. Food & drug Administration (FDA) for their product-Xpert Xpress SARS-CoV-2, a molecular diagnostic test for detection of SARS-CoV virus. The COVID-19 pandemic has increased the demand for molecular diagnostics to provide proper screening, diagnosis, and treatments for COVID-19. IMPACT ON DEMAND With the ongoing pandemic, the demand for molecular diagnostics products and services has increased. The cases for COVID-19 patients are rapidly increasing, creating a great opportunity for the molecular diagnostics market. To stop the spread of COVID-19 and to treat positive patients, proper diagnosis and treatment are required, which can only be possible through molecular diagnostics instruments, services, software, and others. People suffering from other diseases apart from COVID-19, such as cancer, also require proper medical attention and treatment, increasing the demand for the molecular diagnostics market worldwide. PCR and RT-PCR are some of the important diagnostic instruments required to diagnose positive patients properly. Rising people suffering from COVID-19 and increasing demand for molecular diagnostics enable manufacturers to properly launch proper kits and instruments to detect COVID-19. For instance, · In March 2021, Quidel Corporation expanded its manufacturing facility in California, U.S., to produce Quidel’s popular QuickVue line of products, which helps detect and diagnose COVID-19 infection. · In May 2021, Beckman Coulter, Inc. launched a fully automated and quantitative COVID-19 IgG Test to assess the number of antibodies of COVID-19. · In December 2020, Beckman Coulter, Inc., launched the Access SARS-CoV-2 Antigen assay, a cost-effective and high-throughput COVID-19 test, which is ideal for mass testing in the U.S. · In April 2020, Bio-Rad Laboratories, Inc. launched a serology assay to detect COVID-19 antibodies. · In June 2020, Cepheid announced the development of the next-generation test of the Four-in-One combination test for SARS-CoV-2, Flu A, Flu B, and RSV. The XpertSource: Company Website, Press Releases, DBMR Analysis Xpress SARS-CoV-2/Flu/RSV helps in the detection of 4 viruses from a single patient sample. · In September 2020, QIAGEN launched QIAreach SARS-CoV-2 Antigen Test, which analysis the antigen in less than 15 minutes. This new product launch helps in detecting the COVID-19 virus at a much faster rate. The rising number of launches for COVID-19 test kits and molecular diagnostics tools by manufacturers to offer rapid and accurate analysis of the COVID-19 virus will boost the global molecular diagnostics market growth. Moreover, the demand for molecular diagnostics will be increasing even after COVID-19 to cure and diagnose other diseases. IMPACT ON PRICE The molecular diagnostics instruments are costly as the reagents' needs for it or any other supplies are on the higher side, making the total service costlier. Also, the research and manufacturing of molecular diagnostics products are tedious and time-consuming, making the instrument expensive. Furthermore, instruments, laboratory supervision, utility, space, and supervision ads up to additional prices. The high cost of instrumentation and services for molecular diagnostics makes it hard to afford for lower-class families, restricting the market's growth. Moreover, during a pandemic, the demand for molecular diagnostics products, especially PCR machines, real-time PCR (qPCR) machines, and others, has increased and with rising demand, the prices for services and instruments has also increased. IMPACT ON SUPPLY CHAIN The supply chain for molecular diagnostic tools has decreased initially during COVID-19 as the governmental body has posed restrictions on movements, imports, and export of goods. But with the growing demand and increasing need to diagnose COVID-19 patients and other patients suffering from different diseases such as cancer or infectious diseases, the supply of instruments has increased. With the restriction on movements, the manufacturers could not make instruments and couldn’t export or import the molecular diagnostics tools from one country to another because of restrictions on goods. But after the lockdown is lifted, the supply chain for molecular diagnostics has taken a toll as the need for diagnosis has increased, which ultimately increased the supply for molecular diagnostics instruments, tools, kits, and others. THE RISING COVID-19 CASES ARE LEADING THE MOLECULAR DIAGNOSTICS MARKET. The rising number of COVID-19 patients is increasing the need for molecular diagnostics instruments and services for proper diagnosis and treatment, which will boost market growth in the future. Also, molecular diagnostics are the primary diagnostic tools for rapid and accurate diagnosis and for the screening, isolation, treatment, prevention, and control of COVID‑19. The rise in prevalence of COVID-19 cases is the main factor boosting the growth of the market. For instance, · In July 2021, According to World meters, there are 30,619,932 cases of COVID-19 in India. · In July 2021, According to World Health Organisation (WHO), there are 183,700,343 confirmed cases of COVID-19 patients worldwide. · In January 2020, According to World Health Organisation (WHO), there are 33,378,240 confirmed cases in the U.S. The rise in COVID-19 cases and its proper diagnosis increases the demand for molecular diagnostics. CONCLUSION COVID-19 pandemic has affected the molecular diagnostics market positively. The demand for molecular diagnostics instruments, especially detection kits, PCR and RT-PCR has increased to detect the COVID-19 in patients properly. This factor will boost the growth of the market. During the COVID-19 outbreak, the government also took initiatives to approve diagnostics kits that are urgent and are needed to curb the pandemic situation. The rising need for the proper, rapid, and accurate diagnosis will propel market growth globally. Moreover, the incidence of COVID-19 has increased tremendously, which will propel market growth. Therefore, the need for molecular diagnostics to offer proper treatment to the patient has increased, and the market is expected to boost post-COVID-19 as well.
What COVID-19 Impacted on Cleaning Product in FMCG Industry ?
Impact of COVID-19 on Cleaning Product in FMCG Industry INTRODUCTTION The COVID-19 pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature and lack of availability of its vaccine. As a result, the greatest medical challenge in the 21st century is yet to be faced by physicians worldwide. Though the emergence of the virus can be traced back to Asia, many European countries along with the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. The COVID-19 has been declared as a pandemic by World Health Organization (WHO) due to its increased spread across the globe. After the declaration of the pandemic, various countries announced the complete lockdown such as India, China, and other Asian countries to decrease its spread. According to the latest situation report by World Health Organization (WHO) stated 175 million cases of the corona have been reported globally and 4 million patients are dead due to the coronavirus. On a slightly positive note, a total of 158 million people have recovered and total of 2 million vaccine doses have been administered as well. The sudden shutdown across the word due to COVID-19 pandemic brought daily life to standstill and disturbed all economic activities. It restricted movement of people, induced labor shortages, impacted factory operations, disrupted logistics, led to outlet closures for non-essential products and food service providers, triggered panic buying among consumers for staples and left retailers with stock-outs in few categories. Cleaning products are comprised with numerous types of materials including liquids, powder, sprays, or granules which are used to remove dirt including dust, stain, bad smells, and clutter on surfaces. The main purpose of cleaning products is to maintain health and beauty, removing offensive smells, and avoiding the spread of contaminants to oneself and others. Many cleaning agents can kill bacteria such as kitchen room, as well as bacteria on worktops and other metallic surfaces and clean at the same time. Cleaning products are normally in the form of acids detergents, abrasives, and sanitizers. And others, called degreasers are cleaning agents containing chemical they are used to dissolve water-insoluble substances (such as grease or oil). In the manufacturing sector of cleaning products, workers have been hit hard in some segments, such as workers are told to stay at home, factories have been closed, and global supply chains grind to a halt. Quarantine measures, closure of retail stores, canceled orders, and salary reductions are suppressing demand and supply of the product such as, personal protection equipment, hand sanitizers and delivery of safe food at home. IMPACT ON PRICE The spread of coronavirus has caused huge shortage of cleaning products and due to this shortage, prices have been highly increased. Increases consumption of packaged, healthier, immunity boosting foods and beverages, and hygiene and cleaning products increase intake of OTC medicines to protect from viruses but on other side factories and all nations have gone shut down. These chaos has have had heavy impact on prices of cleaning products. For instance, The average daily sales and factory output have declined. Only few factories are operational in this time and maximum of those factories are in COVID-19 hotspot regions. Due to this condition the government hasn't permitted the distributors to operate, which thereby make sure the shortage of cleaning products and hence, the increased price. IMPACT ON DEMAND The few months of lockdown changes in consumer behavior are being reflected in sales of product categories. Increased awareness about personal hygiene has led to a jump in demand for hand washes and sanitizers. Emphasis on immunity boosting has led to a surge in demand for healthier foods and preventive products. Some categories like grocery, food and home-essential products, are seeing a surge in consumption. Hence, the demand for cleaning products is on the rise which is further leading to growth of the market. During the pandemic, high importance has been provided to cleanliness so as to avoid the spreading of infection. Cleaning is vital to reduce the impact of virus and thus, the demand of cleaning products has been huge. Due to this consumption of cleaning products have also been high and cleaning products are now out of stock. By this contrast, COVID-19 is having a decidedly different effect on various product categories. In particular, the pandemic is elevating the status of household cleaning products. Cleanliness has always been important, but cleaning products are now part of consumer’s daily life. IMPACT ON SUPPLY CHAIN COVID-19 has adversely affected the supply of inputs for many businesses with lockdown policies affecting the movement of people and business operations. In China, people involuntarily sat idle as a result of COVID-19, which led to a diminishing global pipeline of parts and components exporting around the world. Although no major problems have been observed in the supply chains of consumer goods such as sanitizers so far, it remains unclear in the face of an uncertain future. As a result, each country has to realize the severity of the situation and sometimes should tighten or loosen the measures according to the spread of the pandemic. The supply chain also should be flexible enough to respond to the challenges in the supply chain of cleaning products. UPCOMING FUTURE OF PROTECTIVE FILMS MARKET After COVID-19 people are more aware with cleanliness and changed their life style. Moreover, the technology and innovation are creating new cleaning products that consumers are demanding and cleaning companies can use. Additionally, consumers are increasingly more interested in environmentally friendly products. Technology has influenced how cleaning companies manage their business activities and also how they communicate with their customers. In near future social media and innovation will prove important over the coming years. The government has also encouraging cleanness and manufacturers must keep up a constant advertising effort to promote cleanness image and reinforce market presence. Additionally, companies must be quick to meet changing demand and keep up with shifting trends through product innovation and technological savvy. Extending manufacturing lines to include natural and eco-friendly product and packaging options is one way in which companies may need to evolve. STRATEGIC DECISION FOR CLEANING PRODUCT MARKET AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE The spread of coronavirus has caused huge shortage of cleaning products and this shortage has driven price too high. Governments, medical sector staff, workers of other organizations and doctors have been encouraging to use alcohol based hand sanitizers which have had huge impacts on sanitizer market, and have tried their efforts to address and mitigate the challenges of COVID-19 and recover from the economic and social crises. Many country’s government have support packages and while these are not generally specific to the chemical industries. The coronavirus has disrupted almost every industry but governments, medical sectors, workers of other organizations and doctors have encouraged social distancing and due to all these, factories had been shut down and workers were not going to work and have tried their efforts to address and mitigate the challenges of COVID-19 and recover from the economic and social crises. CONCLUSION Pandemic has taken a toll on every aspect of life, including the global economy. With the significant downfalls in many sectors, a collaborative effort of government, industry players, and consumers can win the fight against COVID-19. As official authorities and WHO (World Health Organization) have been encouraging the use of sanitizers, drinking clean water, and hygiene in terms of food we consume and area we live in or washing our hands, the demand for cleaning products has been and will continue to see a significant growth. It still continues to inflict the world with appalling economic and social dilemmas, capable enough to leave severe backlash on the economy for the next several years. The first wave had already inflicted severe blows to the population as well as the economy. The currently experiencing second wave is expected to be more disastrous not only to the masses but also to consumer goods markets. Cleaning products and services are an essential part of preventing and protecting human health during infectious disease outbreaks, including the current COVID-19 pandemic. One of the most cost-effective strategies for increasing pandemic is preparedness, especially in resource-constrained settings, is investing in core public health infrastructure, including water and sanitation systems.